Understanding Data Integrity Violations in Clinical Trial Audits

Introduction: Why Data Integrity Is Central to Clinical Trials

Data integrity underpins the reliability of clinical trial results. Regulatory agencies including the FDA, EMA, and MHRA emphasize that all trial data must be attributable, legible, contemporaneous, original, and accurate (the ALCOA+ principles). Any violation of these principles—such as missing audit trails, unauthorized data changes, or discrepancies between Case Report Forms (CRFs) and source data—can trigger major or critical audit findings.

In recent inspections, regulators have classified data integrity violations as systemic compliance failures. Such deficiencies not only undermine the credibility of trial results but may also delay drug approvals, trigger warning letters, or lead to trial suspension. A well-documented case involved an FDA inspection where falsification of electronic CRFs in a Phase II oncology study resulted in trial data being declared unreliable for regulatory submission.

Regulatory Expectations for Data Integrity

Authorities expect sponsors and CROs to establish strong governance over data management systems. Key requirements include:

• Data must comply with ALCOA+ principles across all stages of collection and reporting.
• Electronic Data Capture (EDC) systems must include audit trails, access controls, and version management.
• Discrepancies between source data and CRFs must be reconciled in real time.
• Sponsors remain accountable for CRO-managed data integrity processes.
• Inspection-ready documentation must be available in the Trial Master File (TMF).

The ClinicalTrials.gov registry highlights the importance of accurate and transparent clinical data entry for regulatory reliability and public trust.

Common Audit Findings on Data Integrity

1. Missing Audit Trails

Auditors frequently report EDC systems lacking audit trails or failing to capture who made data changes, when, and why. This deficiency undermines data accountability.

2. Unauthorized Data Changes

Changes made without proper authorization or documentation are among the most serious audit findings. Regulators view them as red flags for potential data falsification.

3. Source Data vs. CRF Discrepancies

Discrepancies between source documents and CRFs suggest inadequate monitoring or poor site practices, resulting in data inconsistency.

4. CRO Oversight Failures

When data management tasks are outsourced, sponsors often fail to monitor CRO practices adequately. Regulators emphasize that sponsors retain ultimate accountability for data integrity.

Case Study: EMA Inspection on Data Integrity

In a Phase III cardiovascular trial, EMA inspectors found over 100 discrepancies between CRFs and source medical records, along with missing audit trail functionality in the EDC. The findings were classified as critical and delayed submission of the marketing application. The sponsor had to repeat parts of the analysis with corrected data, highlighting the high impact of data integrity lapses on development timelines.

Root Causes of Data Integrity Violations

Analysis of inspection findings shows recurring root causes such as:

• Use of outdated or non-validated EDC systems without audit trails.
• Poorly trained site staff making errors in CRF entries.
• Lack of clear SOPs for managing data entry, correction, and reconciliation.
• Weak sponsor oversight of CRO data management operations.
• Inadequate segregation of duties leading to conflicts of interest in data handling.